Status In progress
Process STA 2018
ID number 1101

Provisional Schedule

Committee meeting: 1 24 March 2020
Expected publication 10 June 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Portola Pharmaceuticals
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Anticoagulation UK
  Thrombosis UK
Professional groups British Society for Haematology
  British Society of Gastroenterology
  British Society of Interventional Radiology
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies Bristol-Myers Squibb (not comparator but relevant company)
General commentators All Wales Therapeutics and Toxicology Centre
  Department of Health and Social Service and Public Safety - Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
23 September 2019 The timelines for this appraisal have been revised. NICE have agreed to allow the company additional time to update their submission in response to the Evidence Review Group's clarification questions. The first committee meeting is now expected to take place on Tuesday 24 March 2020.
10 April 2019 Invitation to participate
30 November 2018 - 21 December 2018 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 November 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance